Should I buy or sell Calliditas Therapeutics AB (publ) stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CALT shares. View CALT analyst ratings or view top-rated stocks .

What is Calliditas Therapeutics AB (publ)'s stock price target for 2024?

2 brokerages have issued 1-year target prices for Calliditas Therapeutics AB (publ)'s shares. Their CALT share price targets range from $18.00 to $50.00. On average, they expect the company's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 92.6% from the stock's current price. View analysts price targets for CALT or view top-rated stocks among Wall Street analysts .

How have CALT shares performed in 2024?

Calliditas Therapeutics AB (publ)'s stock was trading at $25.74 at the beginning of the year. Since then, CALT stock has decreased by 31.4% and is now trading at $17.65. View the best growth stocks for 2024 here .

Are investors shorting Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 3,200 shares, a decline of 56.2% from the March 15th total of 7,300 shares. Based on an average daily trading volume, of 7,900 shares, the short-interest ratio is currently 0.4 days. View Calliditas Therapeutics AB (publ)'s Short Interest .

When is Calliditas Therapeutics AB (publ)'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our CALT earnings forecast .

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings data on Wednesday, February, 21st. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. The firm had revenue of $42.45 million for the quarter, compared to analyst estimates of $36.24 million. Calliditas Therapeutics AB (publ) had a negative trailing twelve-month return on equity of 104.47% and a negative net margin of 38.72%. During the same period in the previous year, the business earned ($0.01) EPS.

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Trevena (TRVN) , Advanced Micro Devices (AMD) , ChromaDex (CDXC) , Chimerix (CMRX) , CTI BioPharma (CTIC) , DRDGOLD (DRD) , Forte Biosciences (FBRX) .

When did Calliditas Therapeutics AB (publ) IPO?

Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an initial public offering on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel served as the underwriters for the IPO and Carnegie was co-manager.

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CALT

Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CALT Stock Alerts

$17.65

-1.09 (-5.82%)

(As of 05:17 PM ET)

Compare

Today's Range: $17.61
▼
$18.82
50-Day Range: $17.55
▼
$23.18
52-Week Range: $15.25
▼
$29.30

Volume: 6,136 shs
Average Volume: 8,129 shs
Market Capitalization: $525.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.00

Get Calliditas Therapeutics AB (publ) alerts:

Calliditas Therapeutics AB (publ) MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 92.6% Upside
$34.00 Price Target
Short Interest: Healthy
0.01% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.02
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 1,089.66%
From $0.29 to $3.45 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.03 out of 5 stars

Medical Sector

343rd out of 918 stocks

Pharmaceutical Preparations Industry

145th out of 405 stocks

3.3

Analyst's Opinion

Consensus Rating
Calliditas Therapeutics AB (publ) has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Calliditas Therapeutics AB (publ) has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.01% of the outstanding shares of Calliditas Therapeutics AB (publ) have been sold short.
Short Interest Ratio / Days to Cover
Calliditas Therapeutics AB (publ) has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Calliditas Therapeutics AB (publ) has recently decreased by 56.16%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Calliditas Therapeutics AB (publ) does not currently pay a dividend.
Dividend Growth
Calliditas Therapeutics AB (publ) does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CALT.

2.8

News and Social Media Coverage

News Sentiment
Calliditas Therapeutics AB (publ) has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Calliditas Therapeutics AB (publ) this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for CALT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Calliditas Therapeutics AB (publ) insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.20% of the stock of Calliditas Therapeutics AB (publ) is held by insiders.
Percentage Held by Institutions
Only 2.83% of the stock of Calliditas Therapeutics AB (publ) is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Calliditas Therapeutics AB (publ) are expected to grow by 1,089.66% in the coming year, from $0.29 to $3.45 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Calliditas Therapeutics AB (publ) is -10.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Calliditas Therapeutics AB (publ) is -10.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Calliditas Therapeutics AB (publ) has a P/B Ratio of 16.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT)

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.

CALT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CALT Stock News Headlines

April 18, 2024 | prnewswire.com

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

April 13, 2024 | americanbankingnews.com

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $21.52

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2024 | americanbankingnews.com

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 8.3%

April 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Calliditas Therapeutics Amid Positive Market Trends and Upcoming Catalysts

April 9, 2024 | finance.yahoo.com

Calliditas Therapeutics to Attend Conferences in April

April 9, 2024 | prnewswire.com

Calliditas Therapeutics to Attend Conferences in April

April 8, 2024 | markets.businessinsider.com

Calliditas Gets Notice Of Allowance For U.S. Patent Application Covering Setanaxib To Treat Cancer

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 8, 2024 | prnewswire.com

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

April 8, 2024 | prnewswire.com

Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment

April 7, 2024 | cnn.com

Calliditas Therapeutics AB Sponsored ADR

March 11, 2024 | prnewswire.com

Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®

March 6, 2024 | finanznachrichten.de

Calliditas Therapeutics: Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO

March 6, 2024 | finanznachrichten.de

Calliditas Therapeutics: Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®

March 6, 2024 | prnewswire.com

Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®

March 1, 2024 | prnewswire.com

Calliditas Therapeutics to Attend Investor Conferences in March

February 26, 2024 | msn.com

Fulcrum Therapeutics Q4 2023 Earnings Preview

February 25, 2024 | msn.com

Calliditas Therapeutics AB (CALT) Price Target Increased by 5.27% to 42.86

February 22, 2024 | finance.yahoo.com

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call Transcript

February 22, 2024 | markets.businessinsider.com

Calliditas Therapeutics: Strong Sales and FDA Approval Propel Buy Rating

February 21, 2024 | prnewswire.com

Calliditas Year-end report, January - December 2023

February 14, 2024 | finance.yahoo.com

Invitation to the presentation of Calliditas´ Year-end report January - December 2023

February 14, 2024 | prnewswire.com

Invitation to the presentation of Calliditas´ Year-end report January - December 2023

February 13, 2024 | msn.com

AN2 Therapeutics extends losses as Leerink cuts on trial setback

February 13, 2024 | finance.yahoo.com

Calliditas provides patent update

January 8, 2024 | finance.yahoo.com

Calliditas Therapeutics provides business update ahead of JP Morgan conference

See More Headlines

Receive CALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CALT
CUSIP: N/A
CIK: 1795579
Web: www.calliditas.se
Phone: 46-0-841-130-05
Fax: N/A
Employees: 192
Year Founded: 2004

Price Target and Rating

Average Stock Price Target: $34.00
High Stock Price Target: $50.00
Low Stock Price Target: $18.00
Potential Upside/Downside: +81.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 64.62
P/E Growth: N/A
Net Income: $-43,960,000.00
Net Margins: -38.72%
Pretax Margin: -37.87%
Return on Equity: -104.47%
Return on Assets: -26.75%

Debt

Debt-to-Equity Ratio: 2.89
Current Ratio: 3.13
Quick Ratio: 3.08

Sales & Book Value

Annual Sales: $113.78 million
Price / Sales: 4.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.06 per share
Price / Book: 17.68

Miscellaneous

Outstanding Shares: 29,790,000
Free Float: 29,135,000
Market Cap: $558.26 million
Optionable: Optionable
Beta: 1.50

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Ms. Renee Aguiar-Lucander (Age 62)
Chief Executive Officer
Comp: $8.99M
Mr. Fredrik Johansson (Age 47)
Chief Financial Officer
Dr. Johan Haggblad Ph.D. (Age 66)
Chief Scientific Officer
Comp: $1.66M
Mr. Brian Gorman (Age 48)
Group General Counsel
Ms. Sandra Frithiof (Age 49)
Head of Human Resources
Ms. Ann-Kristin Myde BSc (Age 69)
Head of Clinical Development & VP of Project Management
Dr. Krassimir Mitchev (Age 65)
Head of Medical Affairs
Dr. Richard S. Philipson M.D. (Age 60)
Chief Medical Officer
Ms. Teona Johnson
Head of US Marketing
Mr. David Ferraro
Head of US Sales

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CALT Stock Analysis - Frequently Asked Questions

Should I buy or sell Calliditas Therapeutics AB (publ) stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CALT shares.
View CALT analyst ratings or view top-rated stocks.
What is Calliditas Therapeutics AB (publ)'s stock price target for 2024?: 2 brokerages have issued 1-year target prices for Calliditas Therapeutics AB (publ)'s shares. Their CALT share price targets range from $18.00 to $50.00. On average, they expect the company's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 92.6% from the stock's current price.
View analysts price targets for CALT or view top-rated stocks among Wall Street analysts.
How have CALT shares performed in 2024?: Calliditas Therapeutics AB (publ)'s stock was trading at $25.74 at the beginning of the year. Since then, CALT stock has decreased by 31.4% and is now trading at $17.65.
View the best growth stocks for 2024 here.
Are investors shorting Calliditas Therapeutics AB (publ)?: Calliditas Therapeutics AB (publ) saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 3,200 shares, a decline of 56.2% from the March 15th total of 7,300 shares. Based on an average daily trading volume, of 7,900 shares, the short-interest ratio is currently 0.4 days.
View Calliditas Therapeutics AB (publ)'s Short Interest.
When is Calliditas Therapeutics AB (publ)'s next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our CALT earnings forecast.

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?: Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings data on Wednesday, February, 21st. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. The firm had revenue of $42.45 million for the quarter, compared to analyst estimates of $36.24 million. Calliditas Therapeutics AB (publ) had a negative trailing twelve-month return on equity of 104.47% and a negative net margin of 38.72%. During the same period in the previous year, the business earned ($0.01) EPS.
What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX).
When did Calliditas Therapeutics AB (publ) IPO?: Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an initial public offering on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel served as the underwriters for the IPO and Carnegie was co-manager.
How do I buy shares of Calliditas Therapeutics AB (publ)?: Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CALT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis

Calliditas Therapeutics AB (publ) MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT)

CALT Stock Price History

CALT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

CALT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™